RVPH Profile
Reviva Pharmaceuticals Holdings, Inc., a clinical-stage biopharmaceutical firm, is dedicated to discovering, developing, and commercializing advanced therapeutics to address significant unmet medical needs across various therapeutic areas. The company's focus encompasses central nervous system (CNS) disorders, respiratory conditions, cardiovascular diseases, metabolic disorders, and inflammatory diseases. Reviva is committed to advancing treatments that offer novel approaches to these challenging medical conditions.
The company’s flagship product candidate, RP5063, is currently undergoing Phase III clinical trials for the treatment of schizophrenia. RP5063 has also completed Phase I clinical trials for a range of psychiatric and neurological conditions including bipolar disorder, major depressive disorder, attention deficit/hyperactivity disorder (ADHD), and behavioral and psychotic symptoms associated with dementia or Alzheimer’s disease. Additionally, RP5063 has been studied for Parkinson’s disease psychosis, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis. This broad therapeutic scope underscores the versatility and potential of RP5063 in addressing diverse and complex medical conditions.
In addition to RP5063, Reviva is advancing RP1208, which is currently in pre-clinical development. RP1208 is being explored for its potential to treat depression and obesity, further expanding the company’s pipeline into critical areas with substantial unmet need. The development of RP1208 highlights Reviva's strategy to leverage innovative science and technology to address a wide array of medical challenges and improve patient outcomes.
Founded and headquartered in Cupertino, California, Reviva Pharmaceuticals Holdings, Inc. is positioned at the forefront of biopharmaceutical innovation. The company continues to advance its pipeline through rigorous research and development, aiming to deliver breakthrough therapies that meet the needs of patients and healthcare providers. With a strategic focus on next-generation therapeutics, Reviva is committed to transforming the treatment landscape for a variety of complex diseases.
|
